Thompson, M., Mato, A., Palomba, L., Leslie, L., Derkach, A., Nemirovsky, D., Islam, P., Geyer, M., Caron, P., Goldberg, A., Kumar, A., Moskowitz, A., Lue, J., Owens, C., Salles, G., Stein, E., Steiner, R., Torka, P., Dahncke, L., Ordona, E., Meem, M., Hutzler, C., Harris, M., Shah, M., Karnam, M., Nogan, L., Maloney, C., Shah, A., Nyima, T., Dorsey, C., Doyle, K., Howgate-Klingaman, J., Brutus, J., Tyznar, D., Lincke, A., Wray, R., Feldman, T., Zelenetz, A., Roeker, L. (2025). A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2025-5676